Exclusive Summary

• The original patent has long expired and it is listed on the WHO Essential Medicines List, indicating zero patent barriers and immediate readiness for global registration and distribution.
• It fulfills the rigid general anesthesia demand of over 300 million human surgeries annually, alongside a massive, highly lucrative veterinary anesthesia market.
• Leveraging the scale advantage of China's pharmaceutical supply chain, production costs are significantly lower than major Western players, ensuring highly attractive profit margins for local distributors.
• Supplied in the standard 100ml clinical format with comprehensive CTD dossiers available, empowering cross-border partners for rapid regulatory approval and a stable, long-term commercial supply.